• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer? Authors' reply.

作者信息

Dulai Parambir S

机构信息

Division of Gastroenterology, University of California, San Diego, CA, USA.

出版信息

Aliment Pharmacol Ther. 2020 Apr;51(7):738-739. doi: 10.1111/apt.15671.

DOI:10.1111/apt.15671
PMID:32162371
Abstract
摘要

相似文献

1
Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer? Authors' reply.社论：一种用于识别在生物时代可能从强化给药中获益最大的患者的临床决策工具——即将实现？作者回复
Aliment Pharmacol Ther. 2020 Apr;51(7):738-739. doi: 10.1111/apt.15671.
2
Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer?
Aliment Pharmacol Ther. 2020 Apr;51(7):737-738. doi: 10.1111/apt.15634.
3
Editorial: the road to elimination of viral hepatitis-another promising real-world experience.社论：消除病毒性肝炎之路——又一次充满希望的现实世界经验。
Aliment Pharmacol Ther. 2020 Jul;52(2):405-406. doi: 10.1111/apt.15837.
4
Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Authors' reply.社论：优特克单抗在305例克罗恩病患者中的真实世界短期疗效——来自ENEIDA注册研究的结果。作者回复
Aliment Pharmacol Ther. 2019 Sep;50(5):600-601. doi: 10.1111/apt.15447.
5
Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort - authors' reply.
Aliment Pharmacol Ther. 2017 Mar;45(6):856-857. doi: 10.1111/apt.13968.
6
Letter: propensity score-handle with care. Authors' reply.
Aliment Pharmacol Ther. 2021 Jan;53(2):362-363. doi: 10.1111/apt.16211.
7
Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.信函：克罗恩病的免疫抑制治疗应从阿达木单抗开始吗？作者回复。
Aliment Pharmacol Ther. 2013 Apr;37(7):752-3. doi: 10.1111/apt.12245.
8
Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors' reply.
Aliment Pharmacol Ther. 2016 Oct;44(7):772-3. doi: 10.1111/apt.13768.
9
Natalizumab for induction of remission in Crohn's disease.那他珠单抗用于诱导克罗恩病缓解
Cochrane Database Syst Rev. 2006 Jul 19(3):CD006097. doi: 10.1002/14651858.CD006097.
10
Editorial: post hoc analysis of SONIC trial--authors' reply.
Aliment Pharmacol Ther. 2015 Jun;41(11):1211. doi: 10.1111/apt.13189.

引用本文的文献

1
Intestinal mRNA expression profiles associated with mucosal healing in ustekinumab-treated Crohn's disease patients: bioinformatics analysis and prospective cohort validation.与乌司奴单抗治疗的克罗恩病患者黏膜愈合相关的肠道 mRNA 表达谱：生物信息学分析和前瞻性队列验证。
J Transl Med. 2024 Jun 26;22(1):595. doi: 10.1186/s12967-024-05427-w.
2
Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn's Disease.临床决策支持工具定义的缓解概率与接受维多珠单抗治疗的克罗恩病患者较低的医疗资源利用相关。
Crohns Colitis 360. 2022 Dec 3;4(4):otac048. doi: 10.1093/crocol/otac048. eCollection 2022 Oct.